May 17, 2007 NASD OTC-BB: MRDAF

LAPEX 2000 LipoLaser Clinical Study Exceeds Expectations

Meridian Co., Ltd. ("Meridian" or the "Company") (OTC BB:MRDAF.OB - News), an industry leader in the research, development, manufacturing and sales of integrative medical equipment, is pleased to announce that it has just completed its double-blind clinical research study under the investigation of Dr. Frank Greenway and Dr. T.S. Guillot, at LSU School of Human Ecology in Louisiana.

The study explored the efficacy of the LAPEX 2000 LipoLaser in body contouring and fat reduction on subjects' waistlines as evidence by girth measurements and photographs. The study concluded that within the study population the LAPEX 2000 LipoLaser provided a significant girth loss that was maintained over repeated treatments that were cumulative over the entire duration of the study.

"The improvement in appearance was evident both clinically and statistically" reports Dr. Frank Greenway, the primary investigator for the study and Medical Director and Professor at the Biomedical Research Centre at the Louisiana State University in Baton Rouge.

Meridian President Hyeon-Seong Myeong commented "we are excited that the study exceeded our objectives in both girth measurements and that there are visible improvements in the photographs."

More About: LAPEX 2000 LipoLaser

The LAPEX 2000 LipoLaser was designed to target the medical and aesthetic market, specifically to address body shaping/contouring, spot fat reduction, and reduction in the appearance of cellulite. The LAPEX 2000 LipoLaser's non-invasive treatment is considered one of the most innovative methods to treat stubborn areas of fat that do not respond to diet and exercise. The demand for this type of treatment is expected to grow rapidly, not only in the plastic surgery profession but non-clinical settings such as spas and wellness centers that treat localized body fat deposits which may not have responded to diet and exercise.

More About: Meridian

Meridian is an established leader in the research/development, manufacturing and sales of advanced medical devices in the healthcare industry. With a dynamic research and development team, Meridian is at the forefront in the development of cutting edge medical technologies. The Company presently holds a total of 18 worldwide patents on its technology, and has received approvals from the FDA and other international regulatory agencies, for many of its products. Meridian has over 1500 clients including physicians, hospitals, clinics, healthcare professionals, and wellness centers in Korea, USA, Canada, China, Japan and Europe, and continues to successfully market its superior product line to a growing number of clients worldwide.

On Behalf of the Board of Directors,

Hyeon Seong Myeong, President

This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the Company.

Contacts:
Meridian Co., Ltd.
Peter Holeczek
Corporate Communications
1-866-736-3306
Website: https://MeridianMedical.ca